Evidence map›Paper›PMID 33315938›Full record

ArticlePLoS pathogens2020

Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment.

Jennifer A Bartell, David R Cameron, Biljana Mojsoska, Janus Anders Juul Haagensen, Tacjana Pressler, Lea M Sommer, Kim Lewis, Søren Molin, Helle Krogh Johansen

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 80 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Article
  11. Biofilm Formation ofMicroorganisms · 2025
    Review
  12. Surviving Colonies ofAntibiotics (Basel, Switzerland) · 2025
    Article
  13. Eradication ofACS infectious diseases · 2024
    Article
  14. Article
  15. Tracking the progeny of bacterial persisters using a CRISPR-based genomic recorder.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Review
  17. Article
  18. Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Jennifer A BartellThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.
David R CameronAntimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, Massachusetts, United States of America.
Biljana MojsoskaDepartment of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
Janus Anders Juul HaagensenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.
Tacjana PresslerCystic Fibrosis Center, Rigshospitalet, Copenhagen, Denmark.
Lea M SommerDepartment of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
Kim LewisAntimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, Massachusetts, United States of America.
Søren MolinThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.
Helle Krogh JohansenDepartment of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-0268-3717
Novo Nordisk Foundation · DKRigshospitalet · DKNortheastern University · USUniversity of Bern · CHUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite intensive antibiotic treatment, Pseudomonas aeruginosa often persists in the airways of cystic fibrosis (CF) patients for decades, and can do so without antibiotic resistance development. Using high-throughput screening assays of bacterial survival after treatment with high concentrations of ciprofloxacin, we have determined the prevalence of persisters in a large patient cohort using 460 longitudinal isolates of P. aeruginosa from 39 CF patients. Isolates were classed as high persister variants (Hip) if they regrew following antibiotic treatment in at least 75% of the experimental replicates. Strain genomic data, isolate phenotyping, and patient treatment records were integrated in a lineage-based analysis of persister formation and clinical impact. In total, 19% of the isolates were classified as Hip and Hip emergence increased over lineage colonization time within 22 Hip+ patients. Most Hip+ lineages produced multiple Hip isolates, but few Hip+ lineages were dominated by Hip. While we observed no strong signal of adaptive genetic convergence within Hip isolates, they generally emerged in parallel or following the development of ciprofloxacin resistance and slowed growth. Transient lineages were majority Hip-, while strains that persisted over a clinically diagnosed 'eradication' period were majority Hip+. Patients received indistinguishable treatment regimens before Hip emergence, but Hip+ patients overall were treated significantly more than Hip- patients, signaling repeated treatment failure. When subjected to in vivo-similar antibiotic dosing, a Hip isolate survived better than a non-Hip in a structured biofilm environment. In sum, the Hip phenotype appears to substantially contribute to long-term establishment of a lineage in the CF lung environment. Our results argue against the existence of a single dominant molecular mechanism underlying bacterial antibiotic persistence. We instead show that many routes, both phenotypic and genetic, are available for persister formation and consequent increases in strain fitness and treatment failure in CF airways.

Indexed as

AdultCystic FibrosisFemaleGenetic FitnessHost-Pathogen InteractionsHumansMalePseudomonas aeruginosaPseudomonas Infections

Identifiers

PMID33315938
PMCPMC7769609
OpenAlexW2995568032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.